Baseline A1C ≥ 7.5 Baseline A1C <7.5
Characteristics Bromocriptine-QR
(N = 78)
Placebo
(N = 44)
Bromocriptine-QR
N = 254
Placebo
N = 119
Age 56.4 ± 11.0 59.6 ± 10.9 59.9 ± 9.8 58.7 ± 10.3
% Female 52.6 43.2 57.5 24.0
Race/Ethnicity
   % White
   % Black
   % Hispanic
   % Other
62.8
16.9
15.4
3.8
70.5
9.1
15.9
4.5
66.9
16.9
13.4
2.8
76.5
14.3
8.4
0.8
Weight, kg 94.4 ± 19.4 95.5 ± 20.5 94.3 ± 17.3 97.4 ± 19.2
Body Mass Index, kg/m2 32.9 ± 5.1 32.7 ± 5.2 33.1 ± 5.1 33.6 ± 4.8
Duration of diabetes mellitus, years 7.8 ± 7.5 9.3 ± 7.6 6.9 ± 6.0 6.2  ±4.2
Screening thiazolidinedione
   % Rosiglitazone
   % Pioglitazone
71.0
29.0
59.0
41.0
45.3
54.7
42.9
57.1
Baseline Rosiglitazone Equivalent Dose, mg 5.3 ± 2.3 5.9 ± 2.2 5.1 ± 2.3 5.4 ± 2.4
Hemoglobin A1c ,% 8.2 ± 0.6 8.4 ± 0.7 6.5 ± 0.6 6.4 ± 0.6
Fasting plasma glucose, mg/dl 172 ± 39.7 175 ± 44.1 125 ± 25 126 ± 26
Systolic Blood Pressure, mmHg 129 ± 13.4 131 ± 14.3 129 ± 14 128 ± 13
Diastolic Blood Pressure, mmHg Baseline Diabetic Therapy at Baseline 76.9 ± 7.9 76.9 ± 9.6 77 ± 8 77 ± 9
  % Taking thiazolidinedione only
  % Taking TZD with Metformin
  % Taking TZD with Sulfonylurea
  % Taking TZD with Other Oral Diabetes Med
17
60
22
3
18
43
39
2.3
37
50
14
0.4
40
30
4
0.8
Data presented as mean ± standard deviation (unless otherwise specified)
Table 1: Baseline demographic and clinical characteristics of the study population.